Targeting Androgen Receptor Function by MicroRNA in Prostate Cancer
Annual rept. 1 Jan 2007-30 Jun 2008
CLEVELAND CLINIC FOUNDATION OH
Pagination or Media Count:
Prostate cancer is the most commonly diagnosed and second most deadly cancer in North American men and the blockade of androgen action through the AR has been the cornerstone of systemic therapy of prostate cancer. However, the effectiveness of this therapy is rather transient which inevitably fails and tumor growth resumes despite androgen blockade. The failure of AR receptor antagonists results in higher levels of AR protein which promotes the development of androgen-independent prostate cancer. Originally we proposed the utilization of micro mi RNAs to blockade the expression of AR in prostate carcinoma cells. We have identified a few miRNAs that can repress the AR protein synthesis in prostate carcinoma cells. Our long-term goals are to identify naturally occurring miRNAs that have potential to block the activity of AR and to improvise their efficacy by rational designing to provide novel AR Antagonist miRNAs .
- Anatomy and Physiology
- Medicine and Medical Research